Effect of Shenling Weixiao capsules combined with oxaliplatin and capecitabine chemotherapy regimen in the treatment of spleen-qi deficient colorectal cancer
Objective To investigate the clinical efficacy of Shenling Weixiao capsules combined with XELOX(oxaliplatin+capecitabine)chemotherapy regimen in the treatment of patients with spleen-qi deficient colorectal cancer.Methods Eighty patients with spleen-qi deficient colorectal cancer treated at the Cangzhou Hospital of Integrated TCM-WM·Hebei from January 2020 to May 2022 were selected as the research subjects.The patients were divided into the control group and the observation group by using the random number table,with 40 patients in each group.The patients in the control group were treated with XELOX regimen,and the patients in the observation group were treated XELOX regimen and Shenling Weixiao capsules.The patients in both groups were treated for 4 treatment cycles,with 21 days as one treatment cycle.After treatment,the clinical efficacy of patients in the two groups was evaluated according to the evaluation criteria in solid tumors,and the traditional Chinese medicine(TCM)syndrome score was recorded.The quality of life of patients in the two groups was assessed by using the functional assessment of cancer theraphy-colorectal(V4.0).Serum levels of tumor markers like squamous cell carcinoma antigen(SCC-Ag),carcinoembryonic antigen(CEA),and carbohydrate antigen 199(CA199)were measured by using the electrochemiluminescence immunoassay.Serum levels of inflammatory factors like tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),C-reactive protein(CRP),and vascular endothelial growth factor(VEGF)were measured by using the enzyme-linked immunosorbent assay.The levels of CD3+,CD4+and CD8+T lymphocyte subpopulations in blood were detected by using the flow cytometry,and the CD4+/CD8+ratio was calculated.The incidence of adverse reactions was recorded.Results The overall effective rate of patients in the observation group[75.0％(30/40)]was significantly higher than that of patients in the control group[52.5％(21/40)](x2=4.381,P＜0.05).There was no statistically significant difference in the TCM syndrome score and the quality of life score between the two groups before treatment(P＞0.05).Compared with before treatment,there was a significant decrease in the TCM symptom score and a significant increase in the quality of life score in the two groups after treatment(P＜0.05).After treatment,the TCM symptom score of patients in the observation group was significantly lower than that in the control group,while the quality of life score was significantly higher than that in the control group(P＜0.05).There was no statistically significant difference in serum SCC-Ag,CEA and CA199 levels of patients between the two groups before treatment(P＞0.05).Compared with before treatment,the serum SCC-Ag,CEA and CA199 levels of patients in the two groups were significantly reduced after treatment(P＜0.05).After treatment,the serum SCC-Ag,CEA and CA199 levels of patients in the observation group were significantly lower than those in the control group(P＜0.05).There was no statistically significant difference in the serum levels of TNF-α,IL-6,CRP and VEGF of patients between the two groups before treatment(P＞0.05).Compared with before treatment,the serum levels of TNF-α,IL-6,CRP and VEGF of patients were significantly reduced in the two groups after treatment(P＜0.05).The serum levels of TNF-α,IL-6,CRP and VEGF of patients in the observation group were significantly lower than those in the control group after treatment(P＜0.05).There was no statistically significant difference in the CD3+,CD4+and CD8+levels and the CD4+/CD8+ratio of patients between the two groups before treatment(P＞0.05).Compared with before treatment,the CD3+and CD4+levels and the CD4+/CD8+ratio of patients increased and the CD8+level decreased in the two groups after treatment(P＜0.05).The CD3+and CD4+levels and the CD4+/CD8+ratio were significantly higher and the CD8+level was significantly lower in the observation group than those in the control group after treatment(P＜0.05).The incidence of adverse reactions in the control group and observation group was 32.50％(13/40)and 12.50％(5/40),respectively,and the incidence of adverse reactions in the observation group was significantly lower than that in the control group(x2=4.588,P=0.032).Conclusion Shenling Weixiao capsules combined with XELOX chemotherapy regimen can improve clinical symptoms,reduce inflammatory responses,and enhance the immune function of patients with spleen-qi deficient colorectal cancer.
colorectal cancerspleen-qi deficiencyShenling Weixiao capsulesoxaliplatincapecitabineinflammatory responseimmune function
维普
万方数据
